{"id":19792,"date":"2021-09-27T13:53:35","date_gmt":"2021-09-27T18:53:35","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/ecd-staging\/?post_type=study_trials&#038;p=19792"},"modified":"2021-09-27T13:54:50","modified_gmt":"2021-09-27T18:54:50","slug":"lavdose-selinexor-og-kolinsalicylat-til-behandling-av-pasienter-med-residuelt-tilbakefallende-eller-refraktaert-non-hodgkin-lymfom","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/nb\/study_trials\/low-dose-selinexor-and-choline-salicylate-for-the-treatment-of-patients-with-residual-relapsed-or-refractory-non-hodgkin-lymphoma\/","title":{"rendered":"Lavdose selinexor og kolinsalicylat til behandling av pasienter med residuelt, tilbakefallende eller refrakt\u00e6rt non-Hodgkin-lymfom"},"content":{"rendered":"<p><strong>Form\u00e5let med studien:<\/strong> \u00c5 vurdere den maksimalt tolererte dosen (MTD) av kolinsalicylat (CS) som kan kombineres med selinexor to ganger i uken hos pasienter med tilbakefallende\/refrakt\u00e6rt diffus storcellet B-celle-lymfom (DLBCL) eller mantelcelle-lymfom (MCL). (Prim\u00e6rt)<\/p>\n<p><strong>Prosjektleder:<\/strong> &nbsp;Jonas Paludo, dr. med., Mayo Clinic i Rochester, Minnesota, USA<\/p>\n<p><strong>Kontaktopplysninger:<\/strong> Henvisningskontoret for kliniske studier   Telefon: +1-855-776-0015   E-post: <a href=\"mailto:mayocliniccancerstudies%40mayo.edu?subject=NCT04640779,%20LS1981,%20Low-Dose%20Selinexor%20and%20Choline%20Salicylate%20for%20the%20Treatment%20of%20Patients%20With%20Residual,%20Relapsed%20or%20Refractory%20Non-Hodgkin%20Lymphoma\">mayocliniccancerstudies@mayo.edu<\/a>&nbsp;&nbsp;<\/p>\n<p><strong>\u00d8nsket pasientmedvirkning:<\/strong> 18 \u00e5r og eldre&nbsp;<\/p>\n<p><strong>ClinicalTrials.gov-identifikator:<\/strong> NCT04640779<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective: To evaluate the maximum tolerated dose (MTD) of choline salicylate (CS) that can be combined with selinexor twice weekly in patients with relapsed\/refractory diffuse large B cell lymphoma [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32,129],"class_list":["post-19792","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial","study_trials_cat-interventional"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/study_trials\/19792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/media?parent=19792"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/study_trials_cat?post=19792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}